CPA
OVID icon

Capital Performance Advisors’s Ovid Therapeutics OVID Stock Holding History

Capital Performance Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-146
Closed -$172 – 1912
2024
Q3 		$172 Buy
+146
New +$153 ﹤0.01% 2592

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Performance Advisors's OVID Position: Q4 2024 in Review

Capital Performance Advisors sold out of Ovid Therapeutics (OVID) in Q4 2024, closing a stake of 146 shares — an estimated $172 sold.

Capital Performance Advisors first reported a position in OVID in Q3 2024 and held it in 1 quarter. The position peaked at $172 in Q3 2024. 82 funds tracked by Wall St. Rank hold OVID as of Q4 2024.

  • Capital Performance Advisors reported no remaining Ovid Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 146 Ovid Therapeutics shares in Q4 2024, an estimated $172.
  • Capital Performance Advisors first reported a position in Ovid Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Ovid Therapeutics position peaked at $172 in Q3 2024.
  • 82 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.